DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AGI-1096 is an investigational drug.
There have been 4 clinical trials for AGI-1096. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2003.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Coronary Artery Disease, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are AtheroGenics, Agalimmune Ltd., and Celgene Corporation.
Recent Clinical Trials for AGI-1096
|Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour||Agalimmune Ltd.||Phase 1/Phase 2|
|PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects||Celgene Corporation||Phase 1|
|ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study||AtheroGenics||Phase 2/Phase 3|